2024.02
途深快讯
途深智合 I 连续完成种子轮及天使轮融资
新闻
AI蛋白质设计公司途深智合连续完成种子轮及天使轮融资，两轮投资方分别为光子芯谷、诚美资本。
途深智合成立于2023年，致力于打造高效通用的AI蛋白质设计平台，加速生物科技领域产品的研发。
公司基于其团队技术背景和对市场的深刻理解，开发了集多种先进自研AI模型的蛋白质设计平台 — ProteinEngine，并不断持续迭代。该平台能够完整覆盖蛋白质设计的全流程，实现蛋白质改造与从头设计。ProteinEngine的推出大幅加快酶改造和全新蛋白序列设计过程，并已在食品、医药、化工和医美等多个生物经济领域得到广泛应用，显著提高了众多工业酶、食品添加剂、医药蛋白的活性、产率和功能。
王宇光
途深智合的创始人王宇光博士毕业于新南威尔士大学数学系，现为上海交通大学自然科学研究院副教授，同时担任上海人工智能实验室、上海国家应用数学中心（交大分中心）、张江高等研究院人工智能生物医药中心PI，前马克斯普朗克研究所研究科学家。在人工智能与蛋白设计领域，王宇光已深耕多年，在多个国际顶尖学术期刊会议上发表了逾70篇研究论文，3篇文章获评人工智能顶级会议亮点工作。
途深智合核心团队来自于约翰霍普金斯大学、清华大学、中国科学院等海内外知名高校和研究机构，团队具有丰富的人工智能和生物领域经验。公司由两位AI和计算生物学欧洲科学院院士担任科学顾问，阿联酋技术创新研究院资深首席顾问、Falcon大模型负责人担任科学商务顾问。
目前公司已与国内外多家头部合成生物、医药企业达成合作，在P450蛋白、香兰素催化酶、疫苗抗体等多个领域的产品改造上取得了重大进展。
途深智合的创始人表示：
自AlphaFold 2突破性地解决了超过半个世纪挑战人类智慧的蛋白质折叠难题以来，人工智能在蛋白质工程和生物制药领域扮演的角色日益重要且根本。几何深度学习和大模型在蛋白质结构表示和蛋白序列学习方面的应用，正为蛋白设计领域带来前所未有的变革。这些先进技术通过与生物实验的紧密融合，不仅为蛋白设计乃至整个合成生物的生产链条提供了强大的智能支持工具，还在不断提高生产效率的同时，推动新的合成生物产品的开发和创造。
——途深智合，王宇光
投资人表示：
伴随人工智能快速发展和更新迭代，催生了蛋白质设计行业的重要变革。途深智合是CHIPX和光子芯谷在人工智能领域重点孵化的项目，我们坚定看好团队利用新一代人工智能方法克服传统方法瓶颈，为广泛的合成生物领域所带来的颠覆性创新。团队在创业早期的落地能力令人振奋，CHIPX将持续全方位支持团队产业化发展，以联合创始人角色深度陪跑，加速公司商业化进程。
——种子轮投资方光子芯谷，金贤敏
本轮人工智能技术的突破将会对人类社会产生革命性的影响，诚美资本一直在关注人工智能对各行各业的赋能。途深智合是我们在AI+生物领域中碰到的一个非常优秀的团队。团队成员具有人工智能算法+生物复合背景，技术功底深厚，对行业发展有前瞻认识。公司的AI蛋白质通用设计平台一经推出即获得了国内外头部生物医药企业的认可。我们基金愿意伴随这个团队在AI+生物这个领域不断成长。
——诚美资本，潘阳发
NEWS
AI Protein Design Company Toursun Synbio Successfully Completes Consecutive Seed and Angel Investment Rounds, with Photon Core Valley and ChengMei Capital Serving as the Lead Investors for Each Round
Toursun Synbio, established in 2023, is dedicated to creating an efficient and universal AI protein design platform to accelerate the research and development of biotechnological products.
The company has developed a protein design platform called ProteinEngine, which integrates various advanced proprietary AI models. This platform, which is constantly being iterated, can cover the entire process of protein design, allowing for protein modification and de novo design. The launch of ProteinEngine has significantly accelerated the process of enzyme modification and new protein sequence design and has been widely applied in various bio-economic sectors such as food, medicine, chemicals, and cosmetic surgery, significantly enhancing the activity, yield, and functionality of many industrial enzymes, food additives, and medicinal proteins.
Wang Yuguang
Dr. Wang Yuguang, the founder of Toursun Synbio, graduated from the School of Mathematics and Statistics of the University of New South Wales (UNSW) and is currently an associate professor at the Institute of Natural Sciences at Shanghai Jiao Tong University. He also serves as a principal investigator at the Shanghai Artificial Intelligence Laboratory, Shanghai National Applied Mathematics Center (SJTU branch), and the Zhangjiang Advanced Research Institute AI Biomedicine Center. He was previously a research scientist at the Max Planck Institute. Dr. Wang has been deeply involved in the fields of AI and protein design for many years, publishing over 70 research papers in top international academic journals and conferences, with three papers highlighted in top AI conferences.
The core team of Toursun Synbio consists of individuals from prestigious institutions worldwide, including Johns Hopkins University, Tsinghua University, and the Chinese Academy of Sciences, bringing extensive experience in AI and biology. The company is advised by two European Academy of Sciences academicians in AI and computational biology, a senior chief advisor from the UAE Technology Innovation Institute, and the head of the Falcon big model, serving as scientific and business advisors.
The company has already made significant progress in product modification in various fields such as P450 proteins, vanillin catalyzing enzymes, and vaccine antibodies, through collaborations with leading synthetic biology and pharmaceutical companies both domestically and internationally.
The founder of Toursun Synbio stated：
Since the breakthrough of AlphaFold 2 in solving the protein folding problem that has challenged human intelligence for over half a century, the role of AI in protein engineering and biopharmaceuticals has become increasingly important and fundamental. The application of geometric deep learning and foundation model in protein structure representation and protein sequence learning is bringing unprecedented changes to the field of protein design. These advanced technologies, through close integration with biological experiments, not only provide a powerful intelligent support tool for protein design and the entire synthetic biology production chain but also continuously improve production efficiency while driving the development and creation of new synthetic biology products.
—— Dr. Wang
Regarding the investment：
With the rapid development and iteration of artificial intelligence, a significant transformation has been sparked in the protein design industry. Toursun Synbio is a key project incubated by CHIPX and Photon Core Valley in the field of artificial intelligence, and we are firmly optimistic about the team's ability to overcome traditional bottlenecks using new-generation AI methods, bringing disruptive innovation to the broad field of synthetic biology. The team's capability in early-stage implementation is inspiring, and CHIPX will continue to support the team's industrial development in all aspects, acting as a co-founder to accelerate the commercialization process.
—— Photon Core Valley, the seed round investor, Jin Xianmin
The breakthroughs in artificial intelligence technology will have a revolutionary impact on human society, and ChengMei Capital has always been focused on how AI empowers various industries. Toursun Synbio is an exceptionally talented team we have encountered in the AI+biology field. The team members possess a deep technical foundation in artificial intelligence algorithms and a biological background, with a forward-looking understanding of the industry. The company's AI protein universal design platform has been recognized by leading biopharmaceutical companies domestically and internationally upon its release. Our fund is willing to accompany this team in the AI+biology field for continuous growth.
—— ChengMei Capital, Pan Yangfa
关于我们
途深智合
Toursun Synbio
我们是一家新锐人工智能蛋白质设计企业，核心团队来自于上海交大、清华大学、约翰.霍普金斯大学、新南威尔士大学等世界知名高校。公司致力于运用AI引领蛋白质工程，塑造合成生物学未来，应对全球健康环境挑战。
Toursun Synbio is an emerging enterprise specializing in AI-driven protein design. The core team hails from world-renowned universities such as Shanghai Jiao Tong University, Tsinghua University, Johns Hopkins University, and the University of New South Wales. The company is dedicated to utilizing AI to lead in protein engineering, shaping the future of synthetic biology, and addressing global health and environmental challenges.
联系方式 Contact Us
contact@tsynbio.com
长按识别二维码关注我们
